{"entity":{"id":"nct02716116","kind":"trial","name":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of TAK-788 in non-small-cell lung cancer, run by Takeda, active and no longer recruiting.","summary":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT02716116 by Takeda, with 334 participants enrolled, started 2016-06-16 and due to reach its primary completion in 2026-10-31. Interventions recorded: TAK-788.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02716116","url":"https://clinicaltrials.gov/study/NCT02716116"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc","her2-mutant-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct02716116-jama-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02716116","phase":"1/2","setting":"A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer","sponsor":"Takeda","participation":[{"nct":"NCT02716116","source":"https://clinicaltrials.gov/study/NCT02716116","fetchedAt":"2026-10-07T16:52:49.954Z","studySha256":"c15bf51ed894d106293b63362028a335b70818af60357ea6de22ae42df388d9f","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-02-25","leadSponsor":"Takeda","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":334,"enrolmentType":"ESTIMATED","siteCount":62,"recruitingSiteCount":0,"countries":["China","Germany","Italy","Japan","Puerto Rico","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2016-06-16","startedType":"actual","enrolled":334,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02716116/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}],"paper":[{"id":"paper-nct02716116-jama-oncol-2021","kind":"paper","name":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02716116-jama-oncol-2021/"}]}}